Core Insights - The South Korean cosmetic surgery industry is experiencing rapid growth, particularly in non-invasive procedures such as injectables and laser treatments, which are becoming increasingly popular among consumers [4][13][14] - New injectables like "Rejuran," which uses salmon DNA to enhance skin elasticity, are gaining traction, showcasing the innovative nature of the industry [5][14] - The competitive landscape in South Korea allows for a wide variety of injectables and treatments, often at lower costs compared to other countries, leading to a surge in demand [13][14] Industry Trends - The use of injectables in South Korea has become a mainstream practice, with many clinics offering a plethora of options, including "pink injections" and various types of botulinum toxin [14][19] - There is a notable difference in the regulatory environment between South Korea and the United States, with South Korea allowing more experimental procedures and a broader range of products available to consumers [13][14] - The trend towards non-invasive procedures reflects a shift in consumer preferences, as many seek less painful and lower-risk alternatives to traditional surgeries [13][15] Consumer Behavior - Consumers in South Korea are increasingly viewing cosmetic procedures as a routine part of self-care, leading to a normalization of injectables and other treatments [16][19] - The pressure to conform to beauty standards is significant, with individuals often feeling compelled to undergo procedures to meet societal expectations [16][19] - Despite the risks associated with cosmetic procedures, many consumers accept these as part of the experience, indicating a complex relationship with beauty and self-image [14][19] Medical Practices - The prevalence of cosmetic procedures has raised concerns about safety and the potential for medical errors, with reports of increasing complaints related to cosmetic surgeries [14][15] - Surgeons in South Korea often perform multiple procedures in a day, which may increase the likelihood of mistakes, highlighting the need for careful consideration of patient safety [14][15] - Some medical professionals advocate for a more cautious approach, encouraging patients to reconsider unnecessary procedures and emphasizing the importance of informed decision-making [19][20]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年3月6日， 高德美（Galderma， SIX:GALD ）发布2024年年度财务报告。高德美 专注于皮肤科领域的 全球龙头企业，业务涵盖注射美容、皮肤护理和治疗性皮肤科产品。 2024年财务表现 业务增长驱动因素 注射美容 ：净销售额22.99亿美元，同比增长9.6%。其中，肉毒吉适（Dysport）和聚左旋乳酸填充剂 塑妍萃 （Sculptra）均实现了两位数增长。 产品和市场表现 净销售额 ：达到44.1亿美元（约320亿人民币），按固定汇率计算同比增长9.3%。 核心EBITDA（息税折旧摊销前利润） ：达到10.31亿美元，首次突破10亿美元大关，核心EBITDA利润 率为23.4%，较2023年提高30个基点。 债务杠杆率 ：截至2024年12月，杠杆率降至2.3倍，并成功发行了首笔瑞士债券。 皮肤护理 ：净销售额13.31亿美元，同比增长10.7%。Cetaphil和Alastin品牌表现强劲，尤其是在国际 市场。 治疗性皮肤科 ...